The FDA has granted clearance for NovoPen Echo, the first insulin pen device with half-unit dosing and a memory function that records the dose and elapsed time.

One batch of Semglee prefilled insulin injection pens has been recalled by Mylan Pharmaceuticals for missing labels. Batch No. BF20003118, expiration August 2022 of Semglee (insulin glargine ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday ...

One batch of Semglee prefilled insulin injection pens has been recalled by Mylan Pharmaceuticals for missing labels. Batch No. BF20003118, expiration August 2022 of Semglee (insulin glargine ...

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless non-patented drugmakers such as Biocon Ltd. step in to plug the gap in a ...

MADRID — Day of the week, age, snacking, and being more engaged with smart insulin pens are important factors that affect adherence to injecting bolus insulin in people living with diabetes ...

Smart insulin pens and pumps are advanced medical devices designed to improve diabetes management by providing accurate, real-time data and personalized insulin delivery.

Bluetooth-enabled insulin pens with built-in data-tracking have come a long way in supporting patients since the first FDA-cleared reusable smart insulin pen was launched in 2017.

Sanofi says that since May last year, the Department of Health has faced insulin pen rationing, as the previous sole supplier opted not to tender.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

The model discusses in detail the impact of COVID-19 on Insulin Pens Devices market for the year 2020 and beyond. Insulin pen is used to inject insulin for the treatment of diabetes. It is ...

Eli Lilly ($LLY), one of the big dogs in diabetes treatments, will invest $140 million in a plant on its Indianapolis campus to begin making insulin-filled cartridges for the U.S. market.